| Study | Arm (Dose mg/Day) (N) | Duration (Weeks) | Population Trauma Type | Baseline PTSD Severitya | Mean Age (Y) | % Female | % Non-white | Risk of Bias |
|---|---|---|---|---|---|---|---|---|
| Akuchekian et al., 200477 | Topiramate (12.5 to 500) (34) Placebo (33) | 12 | Male Combat veterans | 49.8 | 40 | 0 | 100 | Medium |
| Batki et al., 2014165 | Topiramate (25 to 300) (14) Placebo (16) | 12 | Veterans w/AUD, warzone and/or civilian related trauma | 72.8 to 83.1 | 50 | 7 | 7 | Low |
| Davidson et al., 2007166 | Tiagabine (4 to 16) (116) Placebo (116) | 12 | Male and female Mixed | 82.6 | 423 | 66 | NR | Medium |
| Davis et al., 2008164 | Divalproex (1,000 to 3,000) (44) Placebo (41) | 8 | Male and female Combat veterans | 75.2 to 77.3 | 55 | 2 | NR | Low |
| Tucker et al., 200778 | Topiramate (25 to 400) (20) Placebo (20) | 12 | Male and female Mixed | 88.3 to 91.1 | 41 | 79 | 11 | Medium |
| Yeh et al., 201179 | Topiramate (25 to 200) (17) Placebo (18) | 12 | Male and female Mixed | 66.1 to 78.8 | 40 | 68 | NR | Medium |
Data reported are mean CAPS or range of mean CAPS scores across groups unless otherwise specified.
AUD = alcohol use disorder; CAPS = Clinician-Administered PTSD Scale; F = female; mg = milligram; N = total number randomized/assigned to intervention and control groups; NR = not reported; PTSD = posttraumatic stress disorder; y = year.
From: Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.